Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Xenobiotica ; 48(12): 1206-1214, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29165024

ABSTRACT

1. Budesonide, a potent topical corticosteroid, reported to have low oral bioavailability in mice, rat, dog and human due to rapid first pass metabolism. However, there is insufficient information available in literature regarding the role of intestine and or liver responsible for the first pass metabolism of budesonide. 2. Current study in rats investigates the role of intestine and liver in first pass metabolism of budesonide using two in vivo models. Additionally, budesonide was also evaluated in in vitro assays such as thermodynamic solubility, permeability in Caco-2 cells and stability in simulated gastric (SGF), intestinal fluids (SIF) to understand the underlaying cause for low oral bioavailability. 3. Budesonide showed low oral, intra-duodenal and high intra-portal bioavailability in rat. In a dual vein cannulated rat model, intestinal and hepatic extraction ratios calculated based upon intestinal availability (Fa·Fg) and hepatic availability (Fh), suggests hepatic extraction of budesonide is minimal compared to intestinal. 4. In vitro results suggest, solubility and permeability may not be a barrier for the observed low oral bioavailability in rats. 5. Correlating the in vitro and in vivo data together, it can be concluded that, intestine might be playing major role in first pass metabolism of budesonide.


Subject(s)
Budesonide/pharmacology , Budesonide/pharmacokinetics , Intestinal Mucosa/metabolism , Liver/metabolism , Animals , Caco-2 Cells , Humans , Male , Rats , Rats, Sprague-Dawley
2.
Bioorg Med Chem ; 25(20): 5799-5819, 2017 10 15.
Article in English | MEDLINE | ID: mdl-28951094

ABSTRACT

A series of terminal nonyl chain and nucleobase modified analogues of (+)-EHNA (III) were synthesized and evaluated for their ability to inhibit adenosine deaminase (ADA). The constrained carbon analogues of (+)-EHNA, 7a-7h, 10a-c, 12, 13, 14 and 17a-c appeared very potent with Ki values in the low nanomolar range. Thio-analogues of (+)-EHNA 24a-e wherein 5'C of nonyl chain replaced by sulfur atom found to be less potent compared to (+)-EHNA. Docking of the representative compounds into the active site of ADA was performed to understand structure-activity relationships. Compounds 7a (Ki: 1.1nM) 7b (Ki: 5.2nM) and 26a (Ki: 5.9nM) showed suitable balance of potency, microsomal stability and demonstrated better pharmacokinetic properties as compared to (+)-EHNA and therefore may have therapeutic potential for various inflammatory diseases, hypertension and cancer.


Subject(s)
Adenine/analogs & derivatives , Adenosine Deaminase Inhibitors/chemistry , Adenine/chemical synthesis , Adenine/chemistry , Adenine/pharmacokinetics , Adenine/pharmacology , Adenosine Deaminase Inhibitors/chemical synthesis , Adenosine Deaminase Inhibitors/pharmacokinetics , Adenosine Deaminase Inhibitors/pharmacology , Catalytic Domain , Enzyme Activation/drug effects , Molecular Docking Simulation , Molecular Structure , Structure-Activity Relationship
3.
Bioorg Med Chem Lett ; 27(8): 1867-1873, 2017 04 15.
Article in English | MEDLINE | ID: mdl-28279528

ABSTRACT

In a pursuit to identify reversible and selective BTK inhibitors, two series based on 7H-pyrrolo[2,3-d]pyrimidine and 1H-pyrrolo[2,3-b]pyridine as the hinge binding core, have been identified. Structure activity relationship (SAR) exploration led to identification of two advanced lead molecules, 11 and 13, which demonstrated desired BTK inhibitory potency in different cellular assays, excellent selectivity in a panel of 50 diverse kinases, favorable in vivo PK properties in mice and anti-arthritic effect in a mouse model of CIA.


Subject(s)
Antirheumatic Agents/chemistry , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/therapeutic use , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyridines/chemistry , Pyridines/therapeutic use , Pyrroles/chemistry , Pyrroles/therapeutic use , Agammaglobulinaemia Tyrosine Kinase , Animals , Antirheumatic Agents/pharmacokinetics , Antirheumatic Agents/pharmacology , Arthritis, Rheumatoid/enzymology , Humans , Male , Mice, Inbred C57BL , Molecular Docking Simulation , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/metabolism , Pyridines/pharmacokinetics , Pyridines/pharmacology , Pyrroles/pharmacokinetics , Pyrroles/pharmacology , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...